Edition:
United States

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

300.52USD
16 Jul 2018
Change (% chg)

$-3.43 (-1.13%)
Prev Close
$303.95
Open
$304.93
Day's High
$304.93
Day's Low
$298.73
Volume
21,533
Avg. Vol
36,253
52-wk High
$305.79
52-wk Low
$209.13

Chart for

About

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $8,966.26
Shares Outstanding(Mil.): 29.80
Dividend: --
Yield (%): --

Financials

  BIO.N Industry Sector
P/E (TTM): 13.16 41.63 33.20
EPS (TTM): 23.09 -- --
ROI: 14.97 14.53 13.23
ROE: 19.36 17.68 15.28

BRIEF-Bio-Rad Q1 Earnings Per Share $21.77

* Q1 EARNINGS PER SHARE VIEW $1.07 -- THOMSON REUTERS I/B/E/S

May 08 2018

BRIEF-Bio Rad Laboratories Says CEO Norman Schwartz's 2017 Total Compensation Was $5.4 Mln Vs $4.9 Mln In 2016

* BIO RAD LABORATORIES INC SAYS CEO NORMAN SCHWARTZ'S 2017 TOTAL COMPENSATION WAS $5.4 MILLION VERSUS $4.9 MILLION IN 2016 – SEC FILING Source text: (https://bit.ly/2KCpD6p) Further company coverage:

May 04 2018

BRIEF-Bio Rad Laboratories Says KPMG Notified Senior Management It Required More Time To Complete Audit Of 2017 Financial Statements

* BIO RAD LABORATORIES - KPMG NOTIFIED SENIOR MANAGEMENT IT REQUIRED MORE TIME TO COMPLETE AUDIT OF 2017 FINANCIAL STATEMENTS - SEC FILING

Mar 16 2018

BRIEF-Bio Rad Laboratories Files For Non-Timely 10-K - SEC Filing

* BIO RAD LABORATORIES FILES FOR NON-TIMELY 10-K - SEC FILING Source text (http://bit.ly/2FeZn29) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 02 2018

BRIEF-Bio-Rad Q4 Earnings Per Share $2.32

* BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Bio-Rad Gains Additional U.S. FDA Clearances

* BIO-RAD GAINS ADDITIONAL U.S. FDA CLEARANCES FOR BLOOD TYPING PRODUCTS, EXPANDING ITS OFFERING FOR BLOOD TESTING MARKET Source text for Eikon: Further company coverage:

Jan 22 2018

Earnings vs. Estimates